heparin + taurocholate

Heparin + taurocholate refers to a **conjugate of heparin and taurocholate**, sometimes further formulated as LHT7 or PEG-LHT7. This conjugate is designed to **reduce the anticoagulant activity of heparin** while leveraging both its and taurocholate’s properties for therapeutic benefit. Heparin is a highly sulfated glycosaminoglycan with potent **anticoagulant** activity through potentiation of antithrombin III, thereby inhibiting clotting factors such as Xa and IIa. Taurocholate is a bile salt that, when conjugated to heparin, alters both structure and biological effects, including *reduced anticoagulant effect* and **enhanced anti-angiogenic and potential anti-tumor activity**[5][1][3]. Heparin-taurocholate conjugates such as LHT7 are being studied as **anti-angiogenic agents, notably inhibiting VEGF-mediated angiogenesis and tumor growth**[5], and as nanocarrier components for targeted drug delivery to tumors, often in combination with other anticancer agents (e.g., TRAIL)[1][3].

Other names

heparin-taurocholate conjugateLHT7LHT-7LHT 7PEG-LHT7PEG-LHT-7PEG-LHT 7